The Axon-Oligodendrocyte Precursor Synapse in NeuroAIDS
The Axon-Oligodendrocyte Precursor Synapse in NeuroAIDS
批准号:
7495852
负责人:
HARRIS A GELBARD
金额:
$23.1万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-05 至 2010-03-31
关键词:
AIDS neuropathyAcuteAffectAntigensAxonBone MarrowBrainBromodeoxyuridineCSPG4 geneCell DeathCellsCentral Nervous System InfectionsChemosensitizationChimera organismChromosome PairingCognitiveCommunicationCorpus CallosumDataDiffusion Magnetic Resonance ImagingDiseaseEvaluationExonsFunctional disorderGlutamate ReceptorGlutamatesHIVHIV Envelope Protein gp120HIV-1Highly Active Antiretroviral TherapyHumanInfectionInfiltrationInflammatoryInjection of therapeutic agentLabelLife Cycle StagesLocalizedMeasuresMediatingMembraneMicrogliaModelingMolecularMonkeysMononuclearMusN-MethylaspartateNG2 antigenNeurologicNeurological statusNeuropathogenesisNeuropsychologyNeurotransmittersOligodendrogliaPathway interactionsPatientsPatternPeripheralPhagocytesPhenotypePopulationProcessRanvier&aposs NodesRecruitment ActivityRegulationRelative (related person)SliceStem cellsStructureSynapsesSynaptic TransmissionSystemTechniquesTestingTetanus Helper PeptideTetracyclineTetracyclinesTimeToxic effectTransgenesTransgenic OrganismsWaxesWeekWild Type Mousealpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acidamino 3 hydroxy 5 methylisoxazole 4 propionateantiretroviral therapybrain tissuedayimmunocytochemistryin vivomacrophagemonocytemotor deficitmutantmyelinationneurotoxicityneurotransmissionoligodendrocyte precursorprecursor cellresearch studyresponsesynaptogenesistherapeutic targetwhite matter
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This R21 application, in response to RFA-MH-08-031, "Mechanisms of HIV Neuropathogenesis: Emerging Domestic and Global Issues," will investigate the molecular mechanisms that give rise to the waxing and waning phenotype of neurologic disease associated with HIV-1 infection of the central nervous system in the years since highly active antiretroviral therapy (HAART) has become the mainstay of therapy. Neuropsychologic and neurologic evaluations demonstrate fluctuant patterns of cognitive and motor deficits that localize in part to the corpus callosum and do not necessarily proceed in an inexorable stepwise pattern of decline that would suggest irrevocable structural damage and cell death in these pathways. Results from diffusion tensor imaging (DTI) neuroradiologic studies of patients with HIV-1 infection and neurologic disease, as well as immunocytochemical studies from human and monkey brain tissue with HIV/SIV infection demonstrate abnormalities in white matter function and axonal structure in the corpus callosum. In contrast, evidence for direct HIV-1 infection of oligodendrocytes in vivo or their cell death remains controversial. While studies have implicated HIV-1 Tat or gp120 in oligodendrocyte dysfunction, the mechanisms for this remain undefined. Here, we will focus on Tat due to its unique ability to modulate synaptic transmission, as well as initiate recruitment and activation of mononuclear cells in the CNS to amplify its neurotoxicity. As a first step in understanding fluctuant changes in neurologic status that are referable in part to damage to the corpus callosum, we will model dysfunction of the corpus callosum in vivo by investigating how HIV-1 Tat may directly or indirectly damage oligodendrocyte precursor cells that are in synaptic communication with axons, and impair axonal conduction in the callosum. This type of synapse is characterized by activity-dependent vesicular release of the excitatory neurotransmitter glutamate from axons and can induce ionotropic currents in [post-synaptic] oligodendrocyte progenitor cells (OPCs) that express the membrane proteoglycan NG2 (NG2+), and ultimately differentiate into oligodendrocytes. We further hypothesize that Tat can recruit infiltrating perivascular macrophages to exacerbate damage to OPC pools, ultimately affecting the ability of OPC to contribute to the population of mature oligodendrocytes that maintains normal callosal structure and function. To test these hypotheses, in aim 1, we will investigate how HIV-1 Tat and infiltrating perivascular macrophages can affect the life cycle of OPC pools and callosal structure and in aim 2, we will investigate how HIV-1 Tat can alter communication between callosal axons and OPCs and investigate whether this in turn impairs axonal conduction in intact brain slices. Data from these experiments will further our understanding of whether damage to components of the axon-OPC synapse contributes to HIV-1 associated neurologic disease and may represent a previously unidentified therapeutic target.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immunovascular interactions in postoperative delirium superimposed on dementia (DSD).
-
批准号:10524797
-
项目类别:
-
资助金额:$224.47万
-
财政年份:2022
-
负责人:HARRIS A GELBARD
-
依托单位:
Nanocrystal Quantum Dot Biomimetics of SARS-CoV-2 to Interrogate Neutrophil-Mediated Neuroinflammation at the Blood-Brain Barrier
-
批准号:10510611
-
项目类别:
-
资助金额:$42.35万
-
财政年份:2022
-
负责人:HARRIS A GELBARD
-
依托单位:
Immunoprofiling postoperative delirium during aging and neurodegeneration
-
批准号:10301230
-
项目类别:
-
资助金额:$23.98万
-
财政年份:2021
-
负责人:HARRIS A GELBARD
-
依托单位:
Immunoprofiling postoperative delirium during aging and neurodegeneration
-
批准号:10456947
-
项目类别:
-
资助金额:$19.85万
-
财政年份:2021
-
负责人:HARRIS A GELBARD
-
依托单位:
MLKi Therapy for Cognitive Impairment in Multiple Sclerosis
-
批准号:8904155
-
项目类别:
-
资助金额:$58.67万
-
财政年份:2015
-
负责人:HARRIS A GELBARD
-
依托单位:
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1
-
批准号:9302543
-
项目类别:
-
资助金额:$63.09万
-
财政年份:2014
-
负责人:HARRIS A GELBARD
-
依托单位:
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1
-
批准号:8893159
-
项目类别:
-
资助金额:$64.18万
-
财政年份:2014
-
负责人:HARRIS A GELBARD
-
依托单位:
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1
-
批准号:8736399
-
项目类别:
-
资助金额:$67.39万
-
财政年份:2014
-
负责人:HARRIS A GELBARD
-
依托单位:
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1
-
批准号:9107504
-
项目类别:
-
资助金额:$63.64万
-
财政年份:2014
-
负责人:HARRIS A GELBARD
-
依托单位:
Core--Cell and Molecular Core Facility
-
批准号:7891347
-
项目类别:
-
资助金额:$21.71万
-
财政年份:2009
-
负责人:HARRIS A GELBARD
-
依托单位:
Core--Biostatistics and Data Management
-
批准号:7891348
-
项目类别:
-
资助金额:$34.21万
-
财政年份:2009
-
负责人:HARRIS A GELBARD
-
依托单位:
Novel HIV Therapies
-
批准号:7891344
-
项目类别:
-
资助金额:$23.43万
-
财政年份:2009
-
负责人:HARRIS A GELBARD
-
依托单位:
Endogenous mechanisms of neuroprotection
-
批准号:7891343
-
项目类别:
-
资助金额:$21.07万
-
财政年份:2009
-
负责人:HARRIS A GELBARD
-
依托单位:
Core--Drug Design for the Molecular Target MLK-3
-
批准号:7891346
-
项目类别:
-
资助金额:$11.83万
-
财政年份:2009
-
负责人:HARRIS A GELBARD
-
依托单位:
Targeted Neuro Protection of HIV-1 Associated Neurologic Disease
-
批准号:7891345
-
项目类别:
-
资助金额:$45.84万
-
财政年份:2009
-
负责人:HARRIS A GELBARD
-
依托单位:
Administrative Core
-
批准号:7944986
-
项目类别:
-
资助金额:$14.09万
-
财政年份:2009
-
负责人:HARRIS A GELBARD
-
依托单位:
Core--Cell and Molecular Core Facility
-
批准号:7664370
-
项目类别:
-
资助金额:$29.29万
-
财政年份:2008
-
负责人:HARRIS A GELBARD
-
依托单位:
Targeted Neuro Protection of HIV-1 Associated Neurologic Disease
-
批准号:7664368
-
项目类别:
-
资助金额:$30.98万
-
财政年份:2008
-
负责人:HARRIS A GELBARD
-
依托单位:
Novel HIV Therapies
-
批准号:7664367
-
项目类别:
-
资助金额:$20.93万
-
财政年份:2008
-
负责人:HARRIS A GELBARD
-
依托单位:
Core--Drug Design for the Molecular Target MLK-3
-
批准号:7664369
-
项目类别:
-
资助金额:$10.49万
-
财政年份:2008
-
负责人:HARRIS A GELBARD
-
依托单位:
海外基金